Dr. Jean L. Grem, MD

Dr. Grem practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Grem's NPI, 1609824424, was assigned on May 4, 2006. Dr. Grem graduated from Jefferson Medical College of Thomas Jefferson University in 1980. Dr. Grem holds Nebraska license 22376.

Dr. Grem's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Grem also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Grem's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Grem is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Grem to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Grem practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Grem's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Grem is licensed in Nebraska.

CMS data shows 858 Medicare services from Dr. Grem across 5 procedure codes in 2024, for 198 Medicare patients. Medicare paid $56,457 for them.

CMS counts 198 Medicare patients who saw Dr. Grem in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have high blood pressure, and 62% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Grem's median patient age at 71, with 59% women.

In 2024, Dr. Grem wrote 1,264 Medicare Part D claims for 133 patients. 90% of them were for generic drugs. CMS names the drug for 1,081 of them, across 38 drugs with 11 or more claims each, at $241,297 in total drug cost. In 2023, CMS named 1,029 claims across 35 drugs.

Dr. Grem accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Grem as offering telehealth.

Dmand AI links 33 papers to Dr. Grem, published from 2012 to 2025. 2013 was the busiest year, with 3. The most frequent topics are Pancreatic Neoplasms, Colonic Neoplasms and Neoplasm Metastasis. Dr. Grem has published most often in J Natl Compr Canc Netw. Dr. Grem's most frequent co-authors are Mary F. Mulcahy, MD, Yi-Jen Chen, MD and Leonard Saltz, MD.

Dmand AI links Dr. Grem to 9 clinical trials, 4 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Rectal Neoplasms, Gallbladder Neoplasms and Adenocarcinoma Of Esophagus. University of Nebraska sponsors the most, 5.

CMS Open Payments shows 12 general payments to Dr. Grem from 10 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $59. It also lists 2 research payments totaling $598 in 2019.

Dr. Grem graduated from Jefferson Medical College of Thomas Jefferson University in 1980.